Pregnancy: ALB has been proven teratogenic in rats and rabbits. Physiological exposure to ALB
and its principal metabolite, ALB sulfoxide, in early human pregnancy is substantially lower than in
the animal species in which teratogenic or embryotoxic effects have been recorded.
Therefore, the risk of fetal exposure from the recommended therapeutic dose is probably very small. Despite the fact that no abnormal birth outcome has been observed following ALB administration during pregnancy, treatment of gravid or potentially gravid females should be avoided, unless the benefit
of treatment significantly outweighs the potential risk to the developing fetus.
Albendazole – mebendazole - praziquantel - World Health Organization (WHO)